Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older, of any gender, with a confirmed diagnosis of an advanced solid tumour or certain blood cancers (including small cell lung cancer, non-small cell lung cancer, colorectal, pancreatic, liver, or ovarian cancer, neuroendocrine tumours, non-Hodgkin's lymphoma, or others) that has stopped responding to standard treatment or for which no standard treatment exists.
• People who have at least one tumour that can be measured on scans, and that shows signs of growth after radiation or local treatment.
• People whose general physical condition is rated as fully active or restricted only in strenuous activity (as assessed using a standard medical scale called ECOG, scoring 0 or 1).
• People whose blood counts and organ function test results meet specific levels, without having received corrective treatments such as growth factor injections or blood transfusions in the two weeks before joining (confirm specific numbers with trial site).
• People who are expected to live for at least three more months.
• People who are able to give voluntary informed consent to participate.
• Women who could become pregnant must be willing to use highly effective contraception throughout the entire treatment period and for 12 weeks after the last dose.
• Male participants must be willing to use condoms throughout the treatment period and for 12 weeks after the last dose, including if their female partner could become pregnant.

Who may not be able to join:

• People who have received any systemic cancer treatment (such as chemotherapy, targeted therapy, immunotherapy, experimental drugs, or anti-cancer herbal medicines) within 21 days before joining, or any blood support therapy within 2 weeks before joining.
• People who are currently taking corticosteroids at a dose greater than 10 mg of prednisone (or an equivalent steroid) per day.
• People who have or have had another separate cancer whose history or treatment could interfere with assessing the safety or effectiveness of the trial drug.
• People with serious or uncontrolled heart conditions, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the past 6 months, significant heart rhythm problems, a heart pumping function below a certain level, certain inherited heart muscle diseases, a history of abnormal heart electrical activity, or coronary artery disease requiring ongoing medication.
• People with high blood pressure at the time of screening, unless it is well controlled on a single blood pressure medication with no changes made in the past 3 months.
• People who are currently coughing up blood, have had significant bleeding within the past 6 months, or have a condition that puts them at clear risk of gastrointestinal bleeding (such as certain swollen veins in the food pipe or active stomach ulcers).
• People with uncontrolled fluid build-up around the lungs, heart, or abdomen.
• People with active or symptomatic cancer that has spread to the brain or spinal cord and requires treatment.
• People who have had a serious blood clot in a deep vein, lungs, or elsewhere within the past 6 months.
• People with lung inflammation or scarring of the lungs that requires treatment, or that is visible on scans at the start of the trial.
• People who still have ongoing side effects from previous cancer treatment rated as moderate or severe (grade 2 or higher), except for hair loss.
• People with significant digestive problems that could affect how the body takes in the study drug, such as an inability to swallow, ongoing severe diarrhoea, or a bowel blockage, or people who have had their entire stomach surgically removed.
• People who have had major surgery within 6 weeks before screening, or minor surgery within 2 weeks before screening.
• People with a high level of protein in their urine, as detected by specific urine tests (confirm thresholds with trial site).
• People with a serious active infection, or a known active infection with hepatitis B, hepatitis C, or HIV/AIDS.
• People with a mental health or cognitive condition that may limit their ability to understand the consent process or follow the study requirements.
• People who have previously had to stop treatment with Aurora kinase inhibitors or certain blood vessel-targeting drugs (such as sorafenib, sunitinib, bevacizumab, or similar medications) because of harmful side effects.
• People with current drug or alcohol use disorders that may affect their ability to take part in the study, as judged by the treating doctor.
• People who are pregnant, planning to become pregnant, currently breastfeeding, or who have a positive pregnancy test before starting the trial.
• People who are currently taking and must continue taking certain medications that strongly affect how the body processes drugs (specific drug classes include strong CYP3A4 inhibitors and inducers — confirm the full list with the trial site).
• People who, for any other reason, are considered by the treating doctor to be unsuitable for participation.

Important: Always verify eligibility with the trial site directly before applying.